In summary, the addition of atezolizumab to nab-paclitaxel could improve the survival time significantly in the PD-L1-positive group, but it is not a cost-effective strategy compared to nab-paclitaxel monotherapy for patients with advanced or metastatic triple-negative breast cancer in the current economic context of China. Here, CD274 is linked to triple-negative breast carcinoma.